PMID- 22010859
OWN - NLM
STAT- MEDLINE
DCOM- 20120828
LR  - 20211203
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 20
IP  - 12
DP  - 2011 Dec
TI  - Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench 
      to bedside.
PG  - 1685-705
LID - 10.1517/13543784.2011.628984 [doi]
AB  - INTRODUCTION: Sarcomas are rare heterogeneous malignancies of mesenchymal origin 
      relatively common during childhood. Disruption of the mammalian target of 
      rapamycin (mTOR) pathway is a very common event during the tumorigenesis of 
      several types of cancer. In particular, strong preclinical evidences suggest 
      pivotal roles of this pathway during the sarcomagenesis. Therefore, the 
      inhibition of mTOR via rapamycin, rapamycin analogs (rapalogs) and 
      ATP-competitive inhibitors seems to be a promising path to follow for a fully 
      tailored therapy. AREAS COVERED: The aim of the present review is to summarize 
      the available data about the mechanisms of mTOR pathway, its biological 
      implications and its possible role in the pathogenesis of soft tissue sarcoma. 
      Moreover, preclinical and clinical evidences of different mTOR inhibitors in the 
      treatment of sarcomas are reported. EXPERT OPINION: Early studies with mTOR 
      inhibitors have demonstrated promising antitumor activity in patients with 
      metastatic sarcoma who have failed standard treatments: that is why mTOR 
      inhibitors represents today a promising chance to improve the prognosis of those 
      patients affected by these rare disease, which is today still extremely poor.
FAU - Vincenzi, Bruno
AU  - Vincenzi B
AD  - University Campus Bio-Medico, Medical Oncology, via Alvaro del Portillo, 200, 
      Rome, Italy.
FAU - Napolitano, Andrea
AU  - Napolitano A
FAU - D'Onofrio, Loretta
AU  - D'Onofrio L
FAU - Frezza, Anna Maria
AU  - Frezza AM
FAU - Silletta, Marianna
AU  - Silletta M
FAU - Venditti, Olga
AU  - Venditti O
FAU - Santini, Daniele
AU  - Santini D
FAU - Tonini, Giuseppe
AU  - Tonini G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111020
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antibiotics, Antineoplastic/*pharmacology/therapeutic use
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Protein Kinase Inhibitors/*pharmacology/therapeutic use
MH  - Sarcoma/*drug therapy/physiopathology
MH  - Signal Transduction/drug effects
MH  - Sirolimus/*pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Translational Research, Biomedical
EDAT- 2011/10/21 06:00
MHDA- 2012/08/29 06:00
CRDT- 2011/10/21 06:00
PHST- 2011/10/21 06:00 [entrez]
PHST- 2011/10/21 06:00 [pubmed]
PHST- 2012/08/29 06:00 [medline]
AID - 10.1517/13543784.2011.628984 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2011 Dec;20(12):1685-705. doi: 
      10.1517/13543784.2011.628984. Epub 2011 Oct 20.